TLC599 is a sustained release therapy for the treatment of osteoarthritis pain. TLC's lipid-based technology allows the use of the corticosteroid dexamethasone in a new formulation that is both fast onset and sustained duration.
- ✔ Category
- ✔ Disease& Specialty
- ✔ R&D Stage
- ✔ Collaboration Option
➤ New Drug
➤ New Formulation
➤ Orthopedics / Musculoskeletal
➤ New Drug
➤ Phase II
➤ Marketing & Distribution
Request for Collaboration
TLC599 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) designed to provide sustained pain management over an extended period of three months or more. TLC599 has the potential to enable patients to receive both immediate and sustained benefit from the local delivery of a highly potent and clinically validated steroid that typically has a very short half-life. Our clinical data suggests that we may be able to achieve a best-in-class duration of action for an intraarticular steroid.
- Encapsulated with the sustained release platform "BioSeizer", phase 1/2 results showed sustained and significant pain control effect at week 12, the end of the observation period
- Phase 1/2 data showed no severe adverse effect in terms of safety profile